1. What is it?
Cortagen consists of four amino acids: alanine, glutamic acid, aspartic acid and proline, abbreviated Ala-Glu-Asp-Pro. It was designed from analyses related to Cortexin, a preparation derived from the cerebral cortex. This does not mean the two products are the same. Cortagen has a defined short structure, while Cortexin contains a mixture of peptides. Findings about such a mixture cannot automatically be attributed to one selected molecule. [95] [97]
2. Why do people turn to it?
Cortagen is associated with hopes of better memory, concentration and repair of damaged nerves. These expectations are mainly based on laboratory and animal experiments. A published paper did examine nerve regrowth after injury, but in rats. Another model assessed animal behaviour after reduced blood supply to the brain. This does not adequately establish similar benefits for someone with memory or sensory problems. The illness and actual patient outcomes need separate investigation. [94] [97]
3. How does it work?
Researchers investigated whether Cortagen affects repair processes and gene activity. Put simply, gene activity describes how actively a cell uses the instructions stored in a gene. A mouse heart study found changes in this activity. Increasing or decreasing it is not automatically beneficial, however. The body needs appropriate regulation, rather than genes simply being switched on. A proposed mechanism therefore remains a research clue until it is linked to a specific improvement in health. [95]
4. What do studies actually show?
In a 2000 paper, rats received Cortagen after their sciatic nerve was cut and stitched together. The authors recorded faster fibre growth and better signal conduction in the regrowing nerve. A 2011 paper described experiments in rats with chronically reduced brain blood supply, including behaviour and biochemical changes. These are different injury models. Neither directly answers whether the peptide helps people after stroke, with diabetic neuropathy or ordinary concentration problems. [94] [97]
5. What do we still not know?
A separate publication analysed blood cells from older people cultured outside the body. It examined changes in genetic-material packing after exposure to short peptides. Participants were not treated, and their memory, functioning and lifespan were not assessed. Another abstract generally refers to earlier clinical benefits, but the study itself concerns mouse hearts. Such an introduction does not replace assessing a specific human study. [96] [95]
6. What are the risks?
The papers found do not allow a reliable estimate of how often Cortagen causes adverse effects in humans, the risks of long-term use or interactions with medicines. They therefore cannot be summarised as showing no side effects. A short chain of amino acids is not a guarantee of safety either. The main gap concerns direct observation of patients: their symptoms, tests of organ function and events after treatment ends. An experiment on an injured animal nerve answers a different question from an overall assessment of human safety. [94] [95] [97]
7. Is it an approved medicine?
Cortagen should not be presented as an established treatment approved in Poland to improve memory or repair nerves. This review found no document confirming such an indication. The cited publications are research papers, not marketing authorizations. Cortexin's status in another country does not determine Cortagen's status. A product needs its own documentation to qualify as an approved medicine; a similar name is not enough. [95] [97]
8. What is new in research?
The search completed on 3 November 2026 found no new, well-described clinical trial confirming the benefits most often expected from Cortagen in humans. Papers from 2000–2011 remain historical starting points, not recent discoveries. Studies in patients with a specific diagnosis, measuring everyday functioning, are most needed. A new cell study could clarify the mechanism but would not alone establish an improvement in patients' lives. [94] [95] [97]
Where does this information come from?
References link to the publications and documents used. Each source includes its material type and what was reviewed; findings concern the substance, form and study population described.
Show sources and how they were checked
- Effect of tetrapeptide cortagen on regeneration of sciatic nerve
December 2000; primary experiment in rats after cutting and repairing the sciatic nerve; PubMed metadata and English abstract reviewed, not the full text. Accessed: 3 November 2026.
- Elucidation of the effect of brain cortex tetrapeptide Cortagen on gene expression in mouse heart by microarray
February/April 2004; primary study of gene expression in mouse hearts; abstract reviewed, earlier clinical reports cited in it were not verified; PubMed metadata and English abstract reviewed, not the full text. Accessed: 3 November 2026.
- Effects of short peptides on lymphocyte chromatin in senile subjects.
January 2004; primary experiment on cultured blood cells taken from older people, not a treatment trial in those people; PubMed metadata and English abstract reviewed, not the full text · DOI: 10.1023/b:bebm.0000024393.40560.05. Accessed: 3 November 2026.
- [Cortexin and cortagen as correcting agents in functional and metabolic disorders in the brain in chronic ischemia].
2011; primary rat study; Russian article, English abstract reviewed; PubMed metadata and English abstract reviewed, not the full text. Accessed: 3 November 2026.